Can paraneoplastic neurologic syndromes precede detection of an occult cancer, while antibody results alone do not prove active malignancy?

Paraneoplastic neurologic syndromes (PNS) may be the first clinically apparent manifestation of an otherwise occult malignancy. Their diagnosis and cancer implications depend on integrated clinical interpretation—not serology in isolation.

Clinical and diagnostic evidence

• Neurologic symptoms can precede cancer detection. This is reflected in PNS-Care guidance recommending prompt, risk-stratified tumor evaluation and, after a negative initial work-up, repeat screening every 4–6 months for 2 years in high-risk phenotype/high-risk antibody settings. Earlier guidance supported surveillance for up to 4 years in selected antibody-positive suspected PNS.
• Antibody positivity is not evidence of contemporaneous active cancer by itself. In one study, definite PNS was identified in 42/46 patients with concordant line-blot plus brain-immunohistochemistry results, versus 4/50 with line-blot-only positivity; cancer was detected in 91% versus 30%, respectively. Another cohort reported an overall onconeural-antibody positive predictive value of 39%.
• The 2021 PNS-Care framework jointly weighs neurologic phenotype, antibody-associated cancer risk, cancer evidence, and follow-up. In a 484-case validation cohort, definite/probable PNS classification had 93% sensitivity and 100% specificity.

Interpretation and cancer assessment

• A compatible phenotype is essential. Low-titer, serum-only, or phenotype-discordant results—especially from commercial line blots—should undergo orthogonal confirmation, potentially through reference-laboratory testing and paired serum/CSF assessment.
• Cancer assessment should be tailored to the phenotype, antibody profile, sex, and likely tumor types. If conventional imaging is unrevealing, whole-body FDG-PET/CT can identify some occult malignancies, although a negative PET/CT does not exclude a small or non–FDG-avid tumor.

Bottom line

• PNS can precede discovery of cancer, but antibodies should trigger targeted confirmation and systematic malignancy evaluation—not be treated as proof of active malignancy.